臨床検査51巻12号

2007年11月発行

特集 遺伝子検査―診断とリスクファクター 4．遺伝子分析―リスクファクターの推定

6) 固形癌

著者： 日野田裕治¹

所属機関： ¹山口大学大学院医学系研究科臨床検査医学分野

ページ範囲：P.1573 - P.1577

はじめに

　この稿では固形癌と関連する遺伝子多型について紹介する．残念ながらこの領域はいまだ診断的価値を議論する段階には到達していない．症例対照研究とそれらをまとめたメタ解析のエビデンスレベルで候補遺伝子多型が決められつつある現状を紹介し，最後に診断応用の可能性について述べたい．

参考文献

1) Lewis SJ, Smith GD：Alcohol, ALDH2, and esophageal cancer：a meta-analysis which illustrates the potentials and limitations of a Mendelian randomization approach. Cancer Epidemiol Biomarkers Prev　14：1967-1971, 2005

2) Saadat M：Genetic polymorphisms of gluthathione S-transferase T1(GSTT1) and susceptibility to gastric cancer：a meta-analysis. Cancer Sci　97：505-509, 2006

3) Boccia S, De Lauretis A, Gianfagna F, et al：CYP2E1PstI/RsaI polymorphism and interaction with tobacco, alcohol and GSTs in gastric cancer susceptibility：a meta-analysis of the literature. Carcinogenesis　28：101-106, 2007

4) Johns LE, Houlston RS：Gluthathione S-transferase mu1(GSTM1) status and bladder cancer risk：a meta-analysis. Mutagenesis　15：399-404, 2000

5) Garcia-Closas M, Malats N, Silverman D, et al：NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer：results from the Spanish Bladder Cancer Study and meta-analyses. Lancet　366：649-659, 2005

6) Houlston RS：CYP1A1 polymorphisms and lung cancer risk：a meta-analysis. Pharmacogenet　10：105-114, 2000

7) Vineis P, Veglia F, Benhamou S, et al：CYP1A1 T3801 C polymorphism and lung cancer：a pooled analysis of 2451 cases and 3358 controls. Int J Cancer　104：650-657, 2003

8) Le Marchand L, Guo C, Benhamou S, et al：Pooled analysis of the CYP1A1 exon 17 polymorphism and lung cancer (United States). Cancer Causes Control　14：339-346, 2003

9) Vineis P, Veglia F, Anttila S, et al：CYP1A1, GSTM1 and GSTT1 polymorphisms and lung cancer：a pooled analysis of gene-gene interactions. Biomarkers　9：298-305, 2004

10) Raimondi S, Boffetta P, Anttila S, et al：Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSCE study. Mutat Res 592：45-57, 2005

11) Feyler A, Voho A, Bouchardy C, et al：Point：myeloperoxidase-463→a polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev　11：1550-1554, 2002

12) Taioli E, Benhamous S, Bouchardy C, et al：Myeloperoxidase G-463A polymorphism and lung cancer：a HuGE genetic susceptibility to environmental carcinogens pooled analysis. Genet Med　9：67-73, 2007

13) Marcus PM, Vineis P, Rothman N：NAT2 slow acetylation and bladder cancer risk：a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenet　10：115-122, 2000

14) Camargo MC, Mera R, Correa P, et al：Interleukin-1 beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer：a meta-analysis. Cancer Epidemiol Biomarkers Prev　15：1674-1687, 2006

15) Wang P, Xia HH, Zhang JY, et al：Association of interleukin-1 gene polymorphisms with gastric cancer：a meta-analysis. Int J Cancer　120：552-562, 2007

16) Kamangar F, Cheng C, Abnet CC, et al：Interleukin-1B polymorphisms and gastric cancer risk-a meta-analysis. Cancer Epiemipl Biomarkers Prev　15：1920-1928, 2006

17) Zintzaras E：Association of methylenetetrahydrofolate reductase (MTHFR) polymorphisms with genetic susceptibility to gastric cancer：a meta-analysis. J Hum Genet　51：618-624, 2006

18) Larsson SC, Giovannucci E, Wolk A：Folate, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer：a meta-analysis. Gastroenterol　131：1271-1283, 2006

19) Huang Y, Han S, Li Y, et al：Different roles of MTHFR C677T and A1298C polymorphisms in colorectal adenoma and colorectal cancer：a meta-analysis. J Hum Genet　52：73-85, 2007

20) Hubner RA, Houlston RS：MTHFR C677T and colorectal cancer risk：a meta-analysis of 25 populations. Int J Cancer　120：1027-1035, 2006

21) Zintzaras E：Methylenetetrahydrofolate reductase gene and susceptibility to breast cancer：a meta-analysis. Clin Genet　69：327-336, 2006

22) Macis D, Maisonneuve P, Johansson H, et al：Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk：a mested-case-control study and a pooled meta-analysis. Breast Cancer Res Treat [Epub ahead of print] 2007

23) Webb EL, Rudd MF, Sellick GS, et al：Search for low penetrance alleles for colorectal cancer through a scan of 1,467 non-synonymous SNPs in 2,575 cases and 2,707 controls with validation by kin-cohort analysis of 14,704 first-degree relatives. Hum Mol Genet　15：3263-3271, 2006

24) Lewis SJ, Harbord RH, Harris R, et al：Meta-analyses of observational and genetic association studies of folate intakes or levels and breast cancer risk. I Natl Cancer Inst　98：1607-1622, 2006

25) Lissowska J, Gaudet MM, Brinton LA, et al：Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk：a population-based case-control study and meta-analyses. Int J Cancer　120：2696-2703, 2007

26) Hung RJ, Hall J, Brennan P, et al：Genetic polymorphism in the base excision repair pathway and cancer risk：a HuGE review. Am J Epidemiol　162：925-942, 2005

27) Kiyohara C, Takayama K, Nakanishi Y：Association of genetic polymorphisms in the base excision repair pathway with lung cancer：a meta-analysis. Lung Cancer　54：267-283, 2006

28) Hu Z, Ma H, Chen F, et al：XRCC1 polymorphisms and cancer risk：a meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev　14：1810-1818, 2005

29) Ewart-Toland A, Dai Q, Gao Y-T, et al：Aurora-A/STK15 T＋91A is a general low penetrance cancer susceptibility gene：a meta-analysis of multiple cancer types. Carcinogenesis　26：1368-1373, 2005

30) Cox DG, Hankinson SE, Hunter DJ：Polymorphisms of the AURKA (STK15/Aurora kinase) gene and breast cancer risk (United States). Cancer Causes Control　17：81-83, 2006

31) The Breast Cancer Association Consortium：Commonly studied single-nucleotide polymorphisms and breast cancer：results from the Breast Cancer Association Consortium. J Natl Cancer Inst　19：1382-1396, 2006